Skeletal Muscle Atrophy and Dysfunction in Human Cancer
Cancer and its treatment can have profound effects on skeletal muscle, the most well-recognized being atrophy, weakness and diminished oxidative capacity. These adaptations negatively impact quality of life, treatment decisions and survival. Despite these consequences, the factors promoting these adaptations remain poorly defined and understudied in human patients. To address this gap in knowledge, our goal in this study is to examine the role of muscle disuse as a regulator of muscle size and function in human cancer patients
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Dec 5, 2023 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Basic Science
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- University of Vermont
- Interventions being studied
- Behavioral: Exercise
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- 50-75 yrs of age
- histologically-documented, stage III or IV non-small cell lung carcinoma (NSCLC)
- estimated life expectancy \>6 mos
- Karnofsky's performance score of ≥70
- history, signs or symptoms of inflammatory or autoimmune disease
- uncontrolled hypertension
- heart or renal failure
- exercise limitations from peripheral vascular disease or stroke
- neuromuscular disease
- knee/hip replacement
- additional, actively-treated malignancy or history of malignancy, except non-melanoma skin cancer
- taking medication that can have anti-coagulant effects that cannot be stopped prior to the muscle biopsy
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Vermont College of MedicineBurlington, Vermont
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 5, 2023. Always confirm current availability with the study team.